UTHR CEO Rothblatt Sells $5M Stock After Pipeline Wins

The chief executive of United Therapeutics picked an interesting moment to monetize a slice of her stock. On May 21, 2026, founder and CEO Martine Rothblatt exercised long-dated options and sold roughly $5.4 million of UTHR on the open market — coming weeks after the biotech reported two pivotal late-stage trial wins that anchor its case for more than $8 billion in eventual annual revenue. For a founder who built a pulmonary-disease franchise and is now chasing manufactured organs, the sale is less a statement than a routine harvest of option value.

That distinction matters because the headline mechanics can mislead. This was an exercise-and-sell: Rothblatt converted vested options struck near $146 into common stock and immediately sold a portion at roughly $558 to $566, capturing the spread. She did not liquidate her stake — she retains a substantial options position and direct common shares, and remains an officer and director of the company she founded. The full picture is on the Rothblatt insider profile.

What the Form 4 shows

The May 21 filing (accession 0001106578-26-000059, viewable on SEC EDGAR) records option exercises (transaction code M) totaling 19,000 shares at a $146.03 strike, paired with eight open-market sale lots (code S) covering 9,500 shares at prices from $557.85 to $566.42 — about $5.4 million in proceeds. The economics are straightforward: with UTHR trading near $566 against a $146 strike, each exercised share carried roughly $420 of embedded gain, and selling a portion covers the exercise cost and tax while leaving the rest invested.

After the activity, Rothblatt's records still show a large retained options position — on the order of 183,000 derivative shares — alongside directly held common stock. This is the signature of compensation harvesting, not a discretionary bet against the company. There is no plan termination or governance event in the filing to suggest otherwise, and the modest size relative to her overall holdings reinforces that read.

Selling into pipeline momentum

The clinical backdrop is unusually rich. United Therapeutics reported first-quarter 2026 net income of $274.9 million on revenue of $781.5 million — a slight miss against the roughly $799 million consensus, which management attributed to operational disruptions. But the quarter's real news was the pipeline. Nebulized Tyvaso met its primary endpoints in two idiopathic pulmonary fibrosis studies (TETON-1 and TETON-2), with an integrated analysis showing a 111.8 mL absolute FVC benefit versus placebo at 52 weeks, and the ADVANCE OUTCOMES trial of oral ralinepag cut the risk of clinical worsening in pulmonary arterial hypertension by 55%.

Tyvaso remains the franchise's engine — about $458 million in the quarter, with the DPI variant up 9% year over year, after total Tyvaso sales rose 16% to $1.88 billion in 2025. Rothblatt framed the quarter as an extension of "our run of clinical success," and management reiterated a target of peak revenue exceeding $8 billion annually by 2027, driven by ralinepag and Tyvaso's expansion into IPF. Against guidance like that, a $5.4 million exercise-and-sell from the founder reads as personal liquidity, not a verdict on the science.

Who owns the other side

United Therapeutics draws a mix of index money and healthcare-specialist conviction. BlackRock tops the 13F holder list, but the standout active holder is Avoro Capital Advisors, a dedicated healthcare investment manager whose presence signals specialist conviction in the pipeline. Wellington Management also features among the active holders, alongside index vehicles Vanguard Portfolio Management, Vanguard Capital Management, and State Street. The full institutional breakdown lives on the UTHR holder page.

What to watch next

Three concrete checkpoints frame the months ahead. First is the regulatory path for nebulized Tyvaso in IPF: with TETON-1 and TETON-2 positive, an FDA filing and decision timeline becomes the single biggest value driver and the clearest catalyst to track. Second is ralinepag's progression toward approval following the ADVANCE OUTCOMES readout. Third is United Therapeutics' second-quarter 2026 earnings report, typically released in late July or early August, which will show whether the Q1 revenue softness was truly a one-quarter operational issue. On the insider side, watch whether Rothblatt's exercise-and-sell stays at this modest cadence — the authoritative record is the primary Form 4 filings, not the day's dollar figure.

FAQ

How much United Therapeutics stock did Martine Rothblatt sell in May 2026?
Rothblatt sold 9,500 UTHR shares for roughly $5.4 million on May 21, 2026, at prices between about $558 and $566, after exercising 19,000 options at a $146.03 strike the same day.

Did Martine Rothblatt exit her United Therapeutics position?
No. The transaction was an exercise-and-sell. She retains a large options position — on the order of 183,000 derivative shares — plus directly held common stock, and remains an officer and director of the company.

Why is United Therapeutics' CEO selling stock now?
The sale captured embedded gain on options struck near $146 against a roughly $566 share price — routine compensation harvesting. It followed strong TETON-1, TETON-2, and ralinepag trial results rather than any negative development.

What did United Therapeutics report for Q1 2026?
Net income of $274.9 million on revenue of $781.5 million, a slight miss on revenue, alongside positive late-stage results for nebulized Tyvaso in IPF and for oral ralinepag in pulmonary arterial hypertension.